Merck said it will withdraw the U.S. accelerated approval indication for Keytruda for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
